Amsacrine
As of the edition of 20 October 2026, Amsacrine is a small molecule: marketed, first approved in 2004 (FR); acts on TOP2A and TOP2B.
Sources: FDA Orange Book and Purple Book, other approval registers, ClinicalTrials.gov, ChEMBL.
The drug
- Status
- Marketed; latest approval 2004
- Kind
- Small molecule
- Brand name
- Amsalyo
- First approved
- 27 February 2004 (FR)
- Approvals on record
- 1 in 1 region
- Holder of the most recent approval
- EUROCEPT INTERNATIONAL (PAYS-BAS)
- Registered trials
- 8, 1 stopped early
- Disease areas
- Blood and lymph; Cancer; Inherited and neonatal
US protection
No US approval on record.
With no US approval on record there are no listed US patents or exclusivities.
This is the US only.
Targets
Registered trials
| Phase | Trials | Completed | Active | Stopped early |
|---|---|---|---|---|
| Phase 2 | 2 | 1 | 1 | 0 |
| Phase 3 | 5 | 3 | 0 | 1 |
| Phase 4 | 1 | 1 | 0 | 0 |
| All trials | 8 |